Liposarcomas

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 939-955

  Henze, Joern ^a   Bauer, Sebastian ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Grading; Liposarcoma; Therapy; Treatment; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CG M097; CGM 097; CYCLIN DEPENDENT KINASE 4; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IFOSFAMIDE; MELPHALAN; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN P53; RG 7112; TRABECTEDIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURVIVOR; CLEAR CELL SARCOMA; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DEDIFFERENTIATED LIPOSARCOMA; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLOW UP; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE MUTATION; HEART LUNG MACHINE; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; LOW DRUG DOSE; META ANALYSIS (TOPIC); MYXOSARCOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEOMORPHIC LIPOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SARCOMA; SMALL CELL SARCOMA; SOFT TISSUE SARCOMA; SPINAL CORD METASTASIS; TUMOR DIFFERENTIATION; WELL DIFFERENTIATED LIPOSARCOMA;

GRADING; LIPOSARCOMA; THERAPY; TREATMENT; TUMOR;

HUMANS; LIPOSARCOMA;

EID: 84884915512     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.010     Document Type: Review

References (102)

1. Mack T.M. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer 1995, 75(1):211-244.
2. Gadgeel S.M., Harlan L.C., Zeruto C.A., et al. Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States. Cancer 2009, 115(12):2744-2754. 10.1002/cncr.24307.
3. Crago A.M., Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011, 23(4):373-378. 10.1097/CCO.0b013e32834796e6.
4. Kindblom L.G., Angervall L., Svendsen P. Liposarcoma: a clinicopathologic, radiographic and prognostic study. Acta Pathol Microbiol Scand Suppl 1975, (253):1-71.
5. Evans H.L. Liposarcoma: a study of 55 cases with reassessment of its classification. Am J Surg Pathol 1979, 3(6):507-523.
6. World Health Organization classification of tumours Pathology and genetics of tumours of soft tissue and bone 2013, IARC Press, Lyon. C.D. Fletcher, K.K. Unni, F. Mertens (Eds.).
7. Fletcher C.D., Bridge J.A., Hogendoorn P.C., et al. WHO classification of tumours of soft tissue and bone 2013, 468. 4th edition.
8. Weiss S.W., Rao V.K. Well-differentiated liposarcoma (atypical lipoma) of deep soft tissue of the extremities, retroperitoneum, and miscellaneous sites. Am J Surg Pathol 1992, 16(11):1051-1058.
9. Kilpatrick S.E., Doyon J., Choong P.F., et al. The clinicopathologic spectrum of myxoid and round cell liposarcoma. Cancer 1996, 77(8):1450-1458.
10. Henricks W.H., Chu Y.C., Goldblum J.R., et al. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Pathol 1997, 21(3):271-281.
11. Gebhard S., Coindre J.M., Michels J.J., et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2002, 26(5):601-616.
12. Hornick J.L., Bosenberg M.W., Mentzel T., et al. Pleomorphic liposarcoma. Am J SurgPathol 2004, 28(10):1257-1267. 10.1097/01.pas.0000135524.73447.4a.
13. Canter R.J., Qin L.X., Ferrone C.R., et al. Why do patients with low-grade soft tissue sarcoma die?. Ann Surg Oncol 2008, 15(12):3550-3560. 10.1245/s10434-008-0163-0.
14. Fletcher C.D., Akerman M., Dal Cin P., et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996, 148(2):623-630.
15. Pedeutour F., Forus A., Coindre J.M., et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999, 24(1):30-41.
16. Binh M., Sastre-Garau X., Guillou L., et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms. Am J Surg Pathol 2005, 29(10):1340-1347.
17. Antonescu C.R., Tschernyavsky S.J., Decuseara R., et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001, 7:3977-3987.
18. Aman P., Ron D., Mandahl N., et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes chromosomes cancer 1992, 5(4):278-285.
19. Knight J.C., Renwick P.J., Cin P.D., et al. Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res 1995, 55:24-27.
20. Rabbitts T.H., Forster A., Larson R., et al. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993, 4(2):175-180.
21. Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992, 6(3):439-453.
22. Powers C.A., Mathur M., Raaka B.M., et al. Is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 1998, 4-18.
23. Kuroda M., Ishida T., Takanashi M., et al. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997, 151(3):735-744.
24. Downes K.A., Goldblum J.R., Montgomery E.A., et al. Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases. Mod Pathol 2001, 14(3):179-184.
25. Mertens F., Fletcher C.D., Dal Cin P., et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosomes Cancer 1998, 22(1):16-25.
26. Schneider-Stock R., Walter H., Radig K., et al. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. JCancer Res Clin Oncol 1998, 124:532-540.
27. Engström K., Bergh P., Gustafson P., et al. Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer 2008, 113(7):1649-1656. 10.1002/cncr.23784.
28. Singer S., Antonescu C.R., Riedel E., et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003, 238(3):358-370. [discussion: 370-1]. 10.1097/01.sla.0000086542.11899.38.
29. Schwab J.H., Boland P.J., Antonescu C., et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007, 110(8):1815-1822. 10.1002/cncr.22992.
30. McCormick D., Mentzel T., Beham A., et al. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 1994, 18(12):1213-1223.
31. Murphy M.D., Arcara L.K., Fanburg-Smith J. Imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation. Radiographics 2005, 25:1371-1395.
32. Linehan D.C., Lewis J.J., Leung D., et al. Influence of biologic factors and anatomic site in completely resected liposarcoma. JClin Oncol 2000, 18(8):1637-1643.
33. Kim H.S., Lee J., Yi S.Y., et al. Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. BMC Cancer 2009, 9:205. 10.1186/1471-2407-9-205.
34. Lucas D.R., Nascimento A.G., Sanjay B.K., et al. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol 1994, 102(5):677-683.
35. Moreau L.C., Turcotte R., Ferguson P., et al. Myxoid\round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol 2012, 19(4):1081-1088. 10.1245/s10434-011-2127-z.
36. McKee M.D., Liu D.F., Brooks J.J., et al. The prognostic significance of margin width for extremity and trunk sarcoma. JSurg Oncol 2004, 85(2):68-76. 10.1002/jso.20009.
37. Liu C.Y., Yen C.C., Chen W.M., et al. Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol 2010, 17(8):2102-2111. 10.1245/s10434-010-0997-0.
38. Rosenberg S.A., Tepper J., Glatstein E., et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluation of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982, 196(3):305-314.
39. Ghert M.A., Abudu A., Driver N., et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity 2005, 12(1):10-17. 10.1245/ASO.2005.03.097.
40. Yang J.C., Chang A.E., Baker A.R., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. JClin Oncol 1998, 16(1):197-203.
41. O'Sullivan B., Davis A.M., Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002, 359(9325):2235-2241. 10.1016/S0140-6736(02)09292-9.
42. Tierney J.F., Stewart L.A., Parmar M.K. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997, 350:1647-1654.
43. Pervaiz N., Colterjohn N., Farrokhyar F., et al. Asystematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113(3):573-581. 10.1002/cncr.23592.
44. Frustaci B.S., Gherlinzoni F., De Paoli A., et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. JClin Oncol 2001, 19(5):1238-1247.
45. Woll P.J., Reichardt P., Le Cesne A., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012, 2045(EORTC 62931):1-10. 10.1016/S1470-2045(12)70346-7.
46. Eilber F.C., Eilber F.R., Eckardt J., et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004, 240(4):686-697. 10.1097/01.sla.0000141710.74073.0d.
47. Lewis J.J., Leung D., Woodruff J.M., et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998, 228(3):355-365.
48. Gronchi A., Lo Vullo S., Fiore M., et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. JClin Oncol 2009, 27(1):24-30. 10.1200/JCO.2008.17.8871.
49. Bonvalot S., Miceli R., Berselli M., et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 2010, 17(6):1507-1514. 10.1245/s10434-010-1057-5.
50. Lienard D., Ewalenko P., Delmotte J.J., et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. JClin Oncol 1992, 10(1):52-60.
51. Eggermont A.M., Schraffordt Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The Cumulative Multicenter European Experience. Ann Surg 1996, 224(6):756-764.
52. Grunhagen D.J., De Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106(8):1776-1784. 10.1002/cncr.21802.
53. Grabellus F., Kraft C., Sheu S.Y., et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol 2009, 16(3):676-686. 10.1245/s10434-008-0277-4.
54. Grabellus F., Kraft C., Sheu-Grabellus S.-Y., et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan. JSurg Oncol 2011, 103(5):371-379. 10.1002/jso.21724.
55. Tepper J.E., Suit H.D. Radiation therapy alone for sarcoma of soft tissue. Cancer 1985, 56:475-479.
56. Kepka L., DeLaney T.F., Suit H.D., et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005, 63(3):852-859. 10.1016/j.ijrobp.2005.03.004.
57. Gortzak E., Azzarelli A., Buesa J., et al. Arandomised phase II study on neo-adjuvant chemotherapy for "high-risk" adult soft-tissue sarcoma. Eur J Cancer 2001, 37(9):1096-1103.
58. DeLaney T.F., Spiro I.J., Suit H.D., et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003, 56(4):1117-1127. 10.1016/S0360-3016(03)00186-X.
59. Kraybill W.G., Harris J., Spiro I.J., et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. JClin Oncol 2006, 24(4):619-625. 10.1200/JCO.2005.02.5577.
60. Kraybill W.G., Harris J., Spiro I.J., et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010, 116(19):4613-4621. 10.1002/cncr.25350.
61. Gronchi A., Bui B.N., Bonvalot S., et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012, 23(3):771-776. 10.1093/annonc/mdr265.
62. Park J.O., Qin L.X., Prete F.P., et al. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma. Ann Surg 2009, 250(6):977-982. 10.1097/SLA.0b013e3181b2468b.
63. Van Geel A.N., Pastorino U., Jauch K., et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Study of 255 Patients. Cancer 1995, 77(4):675-682.
64. Billingsley K.G., Burt M.E., Jara E., et al. Pulmonary metastases from soft tissue sarcoma analysis of patterns of disease and postmetastasis survival. Ann Surg 1999, 229(5):602-612.
65. Rehders A., Hosch S.B., Scheunemann P., et al. Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg 2007, 142(1):70-75. [discussion: 76]. 10.1001/archsurg.142.1.70.
66. Blackmon S.H., Shah N., Roth J.A., et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009, 88(3):877-884. [discussion: 884-5]. 10.1016/j.athoracsur.2009.04.144.
67. Jones R.L., Fisher C., Al-Muderis O., et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005, 41(18):2853-2860. 10.1016/j.ejca.2005.07.023.
68. Italiano A., Toulmonde M., Cioffi A., et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012, 23(6):1601-1607. 10.1093/annonc/mdr485.
69. Patel S.R., Vadhan-Raj S., Papadopolous N., et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. JClin Oncol 1997, 15:2378-2384.
70. Nielsen O.S., Judson I., Van Hoesel Q., et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000, 36(1):61-67.
71. Bitz U., Pink D., Busemann C., et al. Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). JClin Oncol 2011, 29. (suppl; abstr 10094).
72. Demetri G.D., Chawla S.P., Von Mehren M., et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. JClin Oncol 2009, 27(25):4188-4196. 10.1200/JCO.2008.21.0088.
73. Samuels B.L., Chawla S., Patel S., et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013, 24(6):1703-1709. 10.1093/annonc/mds659.
74. Hoiczyk M., Grabellus F., Podleska L., et al. Trabectedin in metastatic soft tissue sarcomas: role of pretreatment and age. Ann Oncol 2013, 43:23-28. 10.3892/ijo.2013.1928.
75. Grosso F., Jones R.L., Demetri G.D., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8:595-602. 10.1016/S1470-2045(07)70175-4.
76. Maki R.G., Wathen J.K., Patel S.R., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. JClin Oncol 2007, 25(19):2755-2763. 10.1200/JCO.2006.10.4117.
77. Sleijfer S., Ray-Coquard I., Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 620. JClin Oncol 2009, 27(19):3126-3132. 10.1200/JCO.2008.21.3223.
78. Van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379(9829):1879-1886. 10.1016/S0140-6736(12)60651-5.
79. Le Cesne A., Judson I., Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. JClin Oncol 2000, 18(14):2676-2684.
80. Katz D., Boonsirikamchai P., Choi H., et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res 2012, 2(1):2. 10.1186/2045-3329-2-2.
81. Italiano A., Garbay D., Cioffi A., et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol 2012, 23(8):2205-2206. 10.1093/annonc/mds221.
82. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003, 13(1):49-58. 10.1016/S1044-579X(02)00099-8.
83. Oren M., Damalas A., Gottlieb T., et al. Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci 2002, 973:374-383.
84. Singer S., Socci N.D., Ambrosini G., et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer research 2007, 67(14):6626-6636. 10.1158/0008-5472.CAN-07-0584.
85. Vassilev L., Vu B., Graves B., et al. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844. 10.1126/science.1092472.
86. Henze J., Mühlenberg T., Simon S., et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One 2012, 7(5):e37776. 10.1371/journal.pone.0037776.
87. Stühmer T., Arts J., King P., et al. Afirst-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells invitro and exvivo. JClin Oncol 2008, 26(suppl; abstr 14694):1-2.
88. Ray-Coquard I.L., Blay J., Italiano A., et al. Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): a pharmacodynamic (PD) biomarker study. JClin Oncol 2011, 29(suppl; abstr 10007b):2-4.
89. Kurzrock R., Blay J., Nguyen B.B., et al. Aphase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. JClin Oncol 2012, 30. (suppl; abstr e136000̂).
90. Ray-Coquard I., Blay J.Y., Italiano A., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13(11):1133-1140. 10.1016/S1470-2045(12)70474-6.
91. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602(1):73-87.
92. Dickson M.A., Keohan M.L., Tap W.D., et al. Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified well-differentiated or dedifferentiated liposarcoma. JClin Oncol 2012, 30. (suppl; abstr 10002).
93. Dickson M.A., Tap W.D., Keohan M.L., et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. JClin Oncol 2013, 31(16):2024-2028. 10.1200/JCO.2012.46.5476.
94. Tontonoz P., Singer S., Forman B.M., et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997, 94(1):237-241.
95. Demetri G.D., Fletcher C.D., Mueller E., et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999, 96(7):3951-3956.
96. Debrock G., Vanhentenrijk V., Sciot R., et al. Aphase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003, 89(8):1409-1412. 10.1038/sj.bjc.6601306.
97. Pishvaian M.J., Cotarla I., Wagner A.J., et al. Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies. JClin Oncol 2010, 28(15s). (suppl; abstr 2526).
98. Charytonowicz E., Terry M., Coakley K., et al. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. JClin Invest 2012, 122(3):886-898. 10.1172/JCI60015DS1.
99. Barretina J., Taylor B.S., Banerji S., et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010, 42(8):715-721. 10.1038/ng.619.
100. Peng T., Zhang P., Liu J., et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 2011, 91(3):392-403. 10.1038/labinvest.2010.185.
101. Gutierrez A., Snyder E.L., Marino-Enriquez A., et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci USA 2011, 108(39):16386-16391. Available at. http://www.pnas.org/cgi/doi/10.1073/pnas.1106127108, 10.1073/pnas.1106127108/-/DCSupplemental.
102. Demicco E.G., Torres K.E., Ghadimi M.P., et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 2012, 25(2):212-221. 10.1038/modpathol.2011.148.